Comparison of epirubicin and doxorubicin cardiotoxicity in children and adolescents treated within the German Cooperative Soft Tissue Sarcoma Study (CWS).
J Cancer Res Clin Oncol
; 132(1): 35-40, 2006 Jan.
Article
em En
| MEDLINE
| ID: mdl-16205946
ABSTRACT
PURPOSE:
Up to now, cardiotoxicity of epirubicin has been studied almost exclusively in adult cancer patients. The aim of this study was to investigate epirubicin in children and adolescents, in comparison with doxorubicin.METHODS:
About 172 soft tissue sarcoma patients (mean age at diagnosis 8.3 years), treated with epirubicin (median cumulative dose 450 mg/m2) or doxorubicin (median cumulative dose 240 mg/m2) within the high-risk group of the CWS-96 study, were examined in a prospective multicentre study. Heart function was analysed by echocardiography, measuring left-ventricular fractional shortening (FS). The median follow up was 27.7 months.RESULTS:
Incidence of clinically manifest cardiomyopathy was 0% (0/60; 95% CI 0-6.0%) in patients treated with epirubicin, and 0.9% (1/108; 95% CI 0-5.1%) in patients treated with doxorubicin. A further three patients showed subclinical cardiomyopathy. There was no difference in FS between the two treatment arms.CONCLUSIONS:
Cardiotoxicity was low in our study. For the short term, cardiotoxicity seems to be only a minor problem in patients treated with epirubicin as applied in this cohort.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Sarcoma
/
Cardiomiopatia Restritiva
/
Epirubicina
/
Doxorrubicina
/
Coração
/
Antibióticos Antineoplásicos
Tipo de estudo:
Clinical_trials
/
Incidence_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Adolescent
/
Child
/
Child, preschool
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
J Cancer Res Clin Oncol
Ano de publicação:
2006
Tipo de documento:
Article